What are the key differences between NMPA Class II and Class III medical device registration in China?

There are over 50 distinct regulatory differences between 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) Class II and Class III medical device registration in China, creating a complex landscape for foreign manufacturers. While Class II devices cover 60% of registered devices, they require only one-third of the documentation that Class III devices demand. Class III devices involve 24-36 months review timelines compared to 12-18 months for Class II, and total costs can range from RMB 500,000 to over RMB 3,000,000 depending on classification and clinical evidence needs. Understanding these differences is critical to avoid delays that can cost foreign firms upwards of RMB 200,000 per month in missed market opportunity.

Regulatory Authority and Approval Process

The most fundamental difference between 二类医疗器械 (Class II medical device, èr lèi yīliáo qìxiè) and 三类医疗器械 (Class III medical device, sān lèi yīliáo qìxiè) is the approving authority. Class II devices are approved at the provincial level by each province’s NMPA branch, while Class III devices require central approval directly from NMPA headquarters in Beijing. This centralization means Class III applications undergo stricter scrutiny, often involving multiple review committees and a formal expert panel evaluation.

For Class II devices, the process begins with submitting technical documents to the provincial authority, which conducts a combined technical review and quality system audit within 120 working days. In sharp contrast, Class III devices require a two-stage review: an initial technical evaluation by the Center for Medical Device Evaluation (CMDE) lasting up to 120 working days, followed by a separate 60-working-day review by NMPA. Overall, Class II registration averages 12-18 months, while Class III spans 24-36 months—a 100% longer timeline.

Clinical Trial Requirements

Clinical trial obligations represent the most significant cost and time driver. Approximately 70% of Class II devices are eligible for clinical trial exemption if they appear on the NMPA’s exempted clinical trial catalog. For example, most non-invasive diagnostic devices and external monitoring devices qualify. However, any Class II device using novel materials or new intended uses may still require clinical data.

Class III devices almost always require 临床试验 (clinical trial, línchuáng shìyàn) unless they are genuinely equivalent to a predicate device that has been on the Chinese market for at least three years. Even then, a head-to-head equivalency study is often mandatory. Class III clinical trials typically involve 200-500 patients at 3-10 Chinese hospitals, costing between RMB 2,000,000 and RMB 8,000,000 and adding 12-18 months to the registration timeline. In contrast, Class II clinical exemptions can save manufacturers up to RMB 1,500,000 and 10 months.

Technical Documentation and Quality System Assessment

The technical dossier for Class III devices is roughly 40-50 documents, versus 20-30 for Class II. Both classes require a quality management system aligned with ISO 13485, but the audit intensity differs markedly. Class II quality system assessments are conducted by provincial authorities over 2-3 days at the manufacturing site. Class III audits are performed by NMPA-designated auditors over 4-5 days and include deeper scrutiny of design controls, risk management, and sterilization validation.

Additionally, Class III devices require submission of a product risk analysis report per GB/T 42062, a clinical evaluation report (CER), and a summary of safety and clinical performance (SSCP) in Chinese. Class II devices typically need only a simplified risk management file and a basic clinical evaluation summary. This documentation burden translates into roughly 6-8 months of additional preparation time for Class III candidates.

Timelines and Costs Comparison Table

Decision Framework for Foreign Manufacturers

If your device is non-invasive, has a clear predicate on the Chinese market, and falls within the NMPA exempted clinical trial catalog, choose Class II registration to save 6-12 months and up to RMB 1,500,000 in clinical trial costs. If your device is implantable, life-supporting, or uses novel technology with no predicate in China, choose Class III registration and prepare for a 24-36 month process with mandatory clinical trials. If your device falls into an ambiguous classification, request a classification determination from NMPA before filing to avoid application rejection.

Post-Market Surveillance Obligations

Once approved, both classes require adverse event reporting within 20 working days for serious incidents, but Class III devices face stricter ongoing obligations. Class III manufacturers must submit Periodic Safety Update Reports (PSURs) every two years, summarizing global clinical data, adverse events, and any corrective actions. Class II manufacturers only need to submit PSURs if significant safety issues arise. Furthermore, Class III devices are subject to random unannounced inspections by NMPA at least once every three years, while Class II devices are inspected primarily if a quality complaint is received.

Three Critical Pitfalls in NMPA Class II vs. Class III Registration

NEXT STEPS

1. Review our comprehensive guide on NMPA Class II registration — includes a step-by-step document checklist and timeline template: /nmpa-class-ii-registration-guide
2. Understand clinical trial requirements for Class III devices — covers hospital selection, CER preparation, and cost estimation: /nmpa-class-iii-clinical-trial-requirements
3. Develop your full China market entry strategy — a decision framework for choosing between Class II and Class III pathways: /china-medical-device-registration-strategy

— China Gateway 360 —
Remote China market entry support, built around execution.

Official Sources

• National Medical Products Administration
• National Health Commission of the People’s Republic of China
• Center for Drug Evaluation, National Medical Products Administration